Item Type | Name |
Academic Article
|
Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
|
Academic Article
|
A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners.
|
Academic Article
|
Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer.
|
Academic Article
|
The Akt inhibitor KP372-1 inhibits proliferation and induces apoptosis and anoikis in squamous cell carcinoma of the head and neck.
|
Academic Article
|
BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation.
|
Academic Article
|
A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase.
|
Academic Article
|
Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor.
|
Academic Article
|
The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.
|
Academic Article
|
Integrin-linked kinase is a potential therapeutic target for anaplastic thyroid cancer.
|
Academic Article
|
Akt inhibitor shows anticancer and radiosensitizing effects in malignant glioma cells by inducing autophagy.
|
Academic Article
|
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer.
|
Academic Article
|
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability.
|
Academic Article
|
Roles of genetic variants in the PI3K and RAS/RAF pathways in susceptibility to endometrial cancer and clinical outcomes.
|
Concept
|
Protein Kinase C
|
Concept
|
DNA-Activated Protein Kinase
|
Concept
|
CDC2 Protein Kinase
|
Concept
|
Protein Kinase Inhibitors
|
Concept
|
Mitogen-Activated Protein Kinase 1
|
Concept
|
Protein Kinase C-alpha
|
Concept
|
Mitogen-Activated Protein Kinase Kinases
|
Concept
|
Calcium-Calmodulin-Dependent Protein Kinase Type 2
|
Concept
|
Mitogen-Activated Protein Kinase 3
|
Concept
|
Mitogen-Activated Protein Kinase Phosphatases
|
Concept
|
Proto-Oncogene Proteins c-akt
|
Academic Article
|
HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells.
|
Academic Article
|
Comprehensive molecular characterization of clear cell renal cell carcinoma.
|
Academic Article
|
Kinome siRNA-phosphoproteomic screen identifies networks regulating AKT signaling.
|
Academic Article
|
Comprehensive molecular characterization of urothelial bladder carcinoma.
|
Academic Article
|
Coordinate phosphorylation of multiple residues on single AKT1 and AKT2 molecules.
|
Academic Article
|
Definition of PKC-a, CDK6, and MET as therapeutic targets in triple-negative breast cancer.
|
Academic Article
|
Association between germline single nucleotide polymorphisms in the PI3K-AKT-mTOR pathway, obesity, and breast cancer disease-free survival.
|
Academic Article
|
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
|
Academic Article
|
A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.
|
Academic Article
|
Genetic events that limit the efficacy of MEK and RTK inhibitor therapies in a mouse model of KRAS-driven pancreatic cancer.
|
Academic Article
|
Transmembrane ion fluxes during activation of human T lymphocytes: role of Ca2+, Na+/H+ exchange and phospholipid turnover.
|
Academic Article
|
Regulation of BAD phosphorylation at serine 112 by the Ras-mitogen-activated protein kinase pathway.
|
Academic Article
|
Phosphorylation and inactivation of glycogen synthase kinase 3 by protein kinase A.
|
Academic Article
|
XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
|
Academic Article
|
Expression of CD26 and its associated dipeptidyl peptidase IV enzyme activity enhances sensitivity to doxorubicin-induced cell cycle arrest at the G(2)/M checkpoint.
|
Academic Article
|
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
|
Academic Article
|
Determinants of rapamycin sensitivity in breast cancer cells.
|
Academic Article
|
The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
|
Academic Article
|
Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors.
|
Academic Article
|
An inherent role of integrin-linked kinase-estrogen receptor alpha interaction in cell migration.
|
Academic Article
|
Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt.
|
Academic Article
|
Pharmacodynamic markers of perifosine efficacy.
|
Academic Article
|
AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27.
|
Academic Article
|
Vimentin is a novel AKT1 target mediating motility and invasion.
|
Academic Article
|
Inhibition of c-Met downregulates TIGAR expression and reduces NADPH production leading to cell death.
|
Academic Article
|
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition.
|
Academic Article
|
Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance.
|
Academic Article
|
Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer.
|
Academic Article
|
Small molecule ErbB inhibitors decrease proliferative signaling and promote apoptosis in philadelphia chromosome-positive acute lymphoblastic leukemia.
|
Academic Article
|
Expression of TTK, a novel human protein kinase, is associated with cell proliferation.
|
Academic Article
|
Antigen-induced Fc receptor-dependent and -independent B cell desensitization. An elevation in [Ca2+]i is not sufficient and protein kinase C activation is not required for these pathways of surface IgM-mediated desensitization.
|
Academic Article
|
Expression of ras oncogene leads to down-regulation of protein kinase C.
|
Academic Article
|
Inhibition of stimulus-dependent epidermal growth factor receptor and transforming growth factor-alpha mRNA accumulation by the protein kinase C inhibitor staurosporine.
|
Academic Article
|
The diacylglycerol analogue, 1,2-sn-dioctanoylglycerol, induces an increase in cytosolic free Ca2+ and cytosolic acidification of T lymphocytes through a protein kinase C-independent process.
|
Academic Article
|
The cell biology of ras-induced transformation: insights from studies utilizing an inducible hybrid oncogene system.
|
Academic Article
|
Osmotic activation of the Na+/H+ antiport in protein kinase C-depleted lymphocytes.
|
Academic Article
|
The SH3 domain of Itk/Emt binds to proline-rich sequences in the cytoplasmic domain of the T cell costimulatory receptor CD28.
|
Academic Article
|
Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits Akt activation and induces anoikis.
|
Academic Article
|
Inhibition of growth-factor-induced phosphorylation and activation of protein kinase B/Akt by atypical protein kinase C in breast cancer cells.
|
Academic Article
|
Sustained activation of JNK/p38 MAPK pathways in response to cisplatin leads to Fas ligand induction and cell death in ovarian carcinoma cells.
|
Academic Article
|
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
|
Academic Article
|
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD and promotes apoptosis in myeloid leukemias.
|
Academic Article
|
Glycogen synthase kinase 3beta is a negative regulator of growth factor-induced activation of the c-Jun N-terminal kinase.
|
Academic Article
|
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
|
Academic Article
|
Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma.
|
Academic Article
|
Autophosphorylation of Akt at threonine 72 and serine 246. A potential mechanism of regulation of Akt kinase activity.
|
Academic Article
|
The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.
|
Academic Article
|
Soft tissue sarcoma cells are highly sensitive to AKT blockade: a role for p53-independent up-regulation of GADD45 alpha.
|
Academic Article
|
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance.
|
Academic Article
|
Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression.
|
Academic Article
|
Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
|
Academic Article
|
Reciprocal regulation of c-Src and STAT3 in non-small cell lung cancer.
|
Academic Article
|
Arsenic trioxide induces a beclin-1-independent autophagic pathway via modulation of SnoN/SkiL expression in ovarian carcinoma cells.
|
Academic Article
|
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.
|
Academic Article
|
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
|
Academic Article
|
Activation of murine double minute 2 by Akt in mammary epithelium delays mammary involution and accelerates mammary tumorigenesis.
|
Academic Article
|
Proteomic profiling identifies pathways dysregulated in non-small cell lung cancer and an inverse association of AMPK and adhesion pathways with recurrence.
|
Academic Article
|
Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition.
|
Academic Article
|
MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells.
|
Academic Article
|
PIK3CA/PTEN mutations and Akt activation as markers of sensitivity to allosteric mTOR inhibitors.
|
Academic Article
|
Biomarkers of response to Akt inhibitor MK-2206 in breast cancer.
|
Academic Article
|
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
|
Academic Article
|
Site-specific activation of AKT protects cells from death induced by glucose deprivation.
|
Academic Article
|
AMPK: a contextual oncogene or tumor suppressor?
|
Academic Article
|
Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.
|
Academic Article
|
Role of protein kinase C in interleukin 1, anti-T3, and mitogenic lectin-induced interleukin 2 secretion.
|
Academic Article
|
Interleukin-2 induces proliferation of T lymphocyte mutants lacking protein kinase C.
|
Academic Article
|
Interleukin 2 activates a receptor-associated protein kinase.
|
Academic Article
|
Interleukin-2 secretion and transmembrane signalling in burned patients.
|
Academic Article
|
Induction of competence and progression signals in human T lymphocytes by phorbol esters and calcium ionophores.
|
Academic Article
|
Expression of human tyrosine kinase-negative epidermal growth factor receptor amplifies signaling through endogenous murine epidermal growth factor receptor.
|
Academic Article
|
Cell cycle dependent regulation of the protein kinase TTK.
|
Academic Article
|
Lysophosphatidylcholine stimulates activator protein 1 and the c-Jun N-terminal kinase activity.
|
Academic Article
|
Lysophosphatidic acid prevents apoptosis in fibroblasts via G(i)-protein-mediated activation of mitogen-activated protein kinase.
|
Academic Article
|
Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo.
|
Academic Article
|
Effect of CD26/dipeptidyl peptidase IV on Jurkat sensitivity to G2/M arrest induced by topoisomerase II inhibitors.
|
Academic Article
|
Targeting the phosphatidylinositol 3-kinase/Akt pathway for enhancing breast cancer cells to radiotherapy.
|
Academic Article
|
Targeting PI3K-AKT pathway for cancer therapy.
|
Academic Article
|
Mammalian target of rapamycin.
|
Academic Article
|
Structure-activity relationships of fluorinated lysophosphatidic acid analogues.
|
Academic Article
|
G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth.
|
Academic Article
|
Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma.
|
Academic Article
|
Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation.
|
Academic Article
|
Cytoplasmic expression of p21CIP1/WAF1 is correlated with IKKbeta overexpression in human breast cancers.
|
Academic Article
|
Point mutations of protein kinases and individualised cancer therapy.
|
Academic Article
|
A new mutational AKTivation in the PI3K pathway.
|
Academic Article
|
An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.
|
Academic Article
|
A novel AKT3 mutation in melanoma tumours and cell lines.
|
Academic Article
|
Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics.
|
Academic Article
|
Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors.
|
Academic Article
|
Physical association of PDK1 with AKT1 is sufficient for pathway activation independent of membrane localization and phosphatidylinositol 3 kinase.
|
Academic Article
|
PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer.
|
Academic Article
|
Identification of optimal drug combinations targeting cellular networks: integrating phospho-proteomics and computational network analysis.
|
Academic Article
|
Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis.
|
Academic Article
|
Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis.
|
Academic Article
|
Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals.
|
Academic Article
|
Akt and ERK control the proliferative response of mammary epithelial cells to the growth factors IGF-1 and EGF through the cell cycle inhibitor p57Kip2.
|
Academic Article
|
AKT-dependent phosphorylation of Niban regulates nucleophosmin- and MDM2-mediated p53 stability and cell apoptosis.
|
Academic Article
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Academic Article
|
Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers.
|
Academic Article
|
A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
|
Academic Article
|
Physiologic activation of protein kinase C limits IL-2 secretion.
|
Academic Article
|
CD28-mediated cytotoxicity by the human leukemic NK cell line YT involves tyrosine phosphorylation, activation of phosphatidylinositol 3-kinase, and protein kinase C.
|
Academic Article
|
Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC.
|
Academic Article
|
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway.
|
Academic Article
|
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
|
Academic Article
|
Genes affecting the cell cycle, growth, maintenance, and drug sensitivity are preferentially regulated by anti-HER2 antibody through phosphatidylinositol 3-kinase-AKT signaling.
|
Academic Article
|
Targeting integrin-linked kinase inhibits Akt signaling pathways and decreases tumor progression of human glioblastoma.
|
Academic Article
|
Differential roles of phosphoinositide-dependent protein kinase-1 and akt1 expression and phosphorylation in breast cancer cell resistance to Paclitaxel, Doxorubicin, and gemcitabine.
|
Academic Article
|
Activation of integrin-linked kinase is a critical prosurvival pathway induced in leukemic cells by bone marrow-derived stromal cells.
|
Academic Article
|
Network topology determines dynamics of the mammalian MAPK1,2 signaling network: bifan motif regulation of C-Raf and B-Raf isoforms by FGFR and MC1R.
|
Academic Article
|
Intratumoral epidermal growth factor receptor antisense DNA therapy in head and neck cancer: first human application and potential antitumor mechanisms.
|
Academic Article
|
PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
|
Academic Article
|
DNA-PK mediates AKT activation and apoptosis inhibition in clinically acquired platinum resistance.
|
Academic Article
|
Dissecting "PI3Kness": the complexity of personalized therapy for ovarian cancer.
|
Academic Article
|
Network analysis of the focal adhesion to invadopodia transition identifies a PI3K-PKCa invasive signaling axis.
|
Academic Article
|
Activation and interaction with protein kinase C of a cytoplasmic tyrosine kinase, Itk/Tsk/Emt, on Fc epsilon RI cross-linking on mast cells.
|
Academic Article
|
Activation of the ras-mitogen-activated protein kinase pathway and phosphorylation of ets-2 at position threonine 72 in human ovarian cancer cell lines.
|
Academic Article
|
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
|
Academic Article
|
Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity.
|
Academic Article
|
Exploiting the PI3K/AKT pathway for cancer drug discovery.
|
Academic Article
|
Simultaneous inhibition of PDK1/AKT and Fms-like tyrosine kinase 3 signaling by a small-molecule KP372-1 induces mitochondrial dysfunction and apoptosis in acute myelogenous leukemia.
|
Academic Article
|
Phosphorylation of beta-catenin by AKT promotes beta-catenin transcriptional activity.
|
Academic Article
|
Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer.
|
Academic Article
|
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition.
|
Academic Article
|
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer.
|
Academic Article
|
Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy.
|
Academic Article
|
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation.
|
Academic Article
|
Targeting tyrosine-kinases and estrogen receptor abrogates resistance to endocrine therapy in breast cancer.
|
Academic Article
|
AKT pathway genes define 5 prognostic subgroups in glioblastoma.
|
Academic Article
|
The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
|
Academic Article
|
Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent?) a VEGFR2/PDGFR?/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial.
|
Academic Article
|
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
|
Academic Article
|
Integrated analysis of transcriptomes of cancer cell lines and patient samples reveals STK11/LKB1-driven regulation of cAMP phosphodiesterase-4D.
|
Academic Article
|
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors.
|
Academic Article
|
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
|
Academic Article
|
P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer.
|
Academic Article
|
Inhibition of mTORC1/2 overcomes resistance to MAPK pathway inhibitors mediated by PGC1a and oxidative phosphorylation in melanoma.
|
Academic Article
|
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer.
|
Academic Article
|
Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma.
|
Academic Article
|
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
|
Academic Article
|
Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities.
|
Academic Article
|
Death-associated protein kinase 1 promotes growth of p53-mutant cancers.
|
Academic Article
|
Genomic Correlate of Exceptional Erlotinib Response in Head and Neck Squamous Cell Carcinoma.
|
Academic Article
|
Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.
|
Academic Article
|
The PI3K/AKT Pathway and Renal Cell Carcinoma.
|
Academic Article
|
A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.
|
Academic Article
|
mTOR Inhibitors Suppress Homologous Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in BRCA-Proficient Triple-Negative Breast Cancer.
|
Academic Article
|
Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma.
|
Academic Article
|
Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion.
|
Academic Article
|
Multiplatform-based molecular subtypes of non-small-cell lung cancer.
|
Academic Article
|
Cell cycle dependent regulation of the protein kinase TTK
|
Academic Article
|
Phosphorylation of the IL2 receptor involves an inducible protein kinase
|
Academic Article
|
A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations.
|
Academic Article
|
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
|
Academic Article
|
PKCiota promotes ovarian tumor progression through deregulation of cyclin E.
|
Academic Article
|
Personalized Preclinical Trials in BRAF Inhibitor-Resistant Patient-Derived Xenograft Models Identify Second-Line Combination Therapies.
|
Academic Article
|
Cardiac glycosides display selective efficacy for STK11 mutant lung cancer.
|
Academic Article
|
Targeting mitochondrial biogenesis to overcome drug resistance to MAPK inhibitors.
|
Academic Article
|
Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
|
Academic Article
|
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
|
Academic Article
|
YAP/TAZ-Mediated Upregulation of GAB2 Leads to Increased Sensitivity to Growth Factor-Induced Activation of the PI3K Pathway.
|
Academic Article
|
ERK and p38 MAPK Activities Determine Sensitivity to PI3K/mTOR Inhibition via Regulation of MYC and YAP.
|
Academic Article
|
PAK signalling drives acquired drug resistance to MAPK inhibitors in BRAF-mutant melanomas.
|
Academic Article
|
PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer.
|
Academic Article
|
Microenvironment-Mediated Mechanisms of Resistance to HER2 Inhibitors Differ between HER2+ Breast Cancer Subtypes.
|
Academic Article
|
EGFR-Phosphorylated Platelet Isoform of Phosphofructokinase 1 Promotes PI3K Activation.
|
Academic Article
|
Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.
|
Academic Article
|
Survival of Cancer Stem-Like Cells Under Metabolic Stress via CaMK2a-mediated Upregulation of Sarco/Endoplasmic Reticulum Calcium ATPase Expression.
|
Academic Article
|
Preclinical evaluation and reverse phase protein Array-based profiling of PI3K and MEK inhibitors in endometrial carcinoma in vitro.
|
Academic Article
|
?-catenin/TCF activity regulates IGF-1R tyrosine kinase inhibitor sensitivity in colon cancer.
|
Academic Article
|
Dual Src and MEK Inhibition Decreases Ovarian Cancer Growth and Targets Tumor Initiating Stem-Like Cells.
|
Academic Article
|
Defective Replication Stress Response Is Inherently Linked to the Cancer Stem Cell Phenotype.
|
Academic Article
|
Deregulated Gab2 phosphorylation mediates aberrant AKT and STAT3 signaling upon PIK3R1 loss in ovarian cancer.
|
Academic Article
|
Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis.
|
Academic Article
|
Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies.
|
Academic Article
|
PIK3CA Amplification Associates with Aggressive Phenotype but Not Markers of AKT-MTOR Signaling in Endometrial Carcinoma.
|
Academic Article
|
Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.
|
Academic Article
|
AKT isoform-specific expression and activation across cancer lineages.
|
Academic Article
|
Protein Kinase C Quality Control by Phosphatase PHLPP1?Unveils Loss-of-Function Mechanism in Cancer.
|
Academic Article
|
GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and ?-catenin activity.
|
Concept
|
Protein Kinase C beta
|
Academic Article
|
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
|
Academic Article
|
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.
|
Academic Article
|
Safety lead-in of the MEK inhibitor trametinib in combination with GSK2141795, an AKT inhibitor, in patients with recurrent endometrial cancer: An NRG Oncology/GOG study.
|
Academic Article
|
MCP-1/CCR-2 axis in adipocytes and cancer cell respectively facilitates ovarian cancer peritoneal metastasis.
|
Academic Article
|
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
|
Academic Article
|
p85? regulates autophagic degradation of AXL to activate oncogenic signaling.
|
Academic Article
|
Fibroblast-tumor cell signaling limits HER2 kinase therapy response via activation of MTOR and antiapoptotic pathways.
|
Academic Article
|
Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models.
|
Academic Article
|
Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
|
Academic Article
|
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer.
|
Academic Article
|
MEK Inhibition Remodels the Immune Landscape of Mutant KRAS Tumors to Overcome Resistance to PARP and Immune Checkpoint Inhibitors.
|
Academic Article
|
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response.
|
Academic Article
|
TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.
|
Academic Article
|
Characterization of anticancer drug resistance by reverse-phase protein array: new targets and strategies.
|
Academic Article
|
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance.
|